Glucocorticoid purchases and methotrexate persistence in early rheumatoid arthritis in Finland

OBJECTIVE: This study aimed to explore purchases of methotrexate (MTX), biological disease-modifying anti-rheumatic drugs (bDMARDs), Janus kinase inhibitors (JAKis), and glucocorticoids (GCs) in early rheumatoid arthritis (RA) in Finland. METHOD: The study included 3046 monitored patients with early RA, who obtained reimbursement for RA medication during 2016-2020. The patients were divided into three groups according to the number of GC tablet purchases during 6 months after the reimbursement day: Group 0, no GC purchases; Group 1, purchased < 90 tablets; Group 2, purchased ≥ 90 tablets. Medication purchases were tracked in 6 month periods until the end of 2021. RESULTS: Of the monitored early RA patients, 68% purchased GCs during the initial 6 months and 43% during 6-11 months after the reimbursement date. Over 90% of the patients purchased MTX during the first year in all groups. Patients in Group 2 had the highest baseline disease activity. After the first year, the percentage of bDMARD purchasers (11% vs 6.8%, p = 0.03) and MTX users (79% vs 74%, p = 0.06) was higher in Group 2 than in Group 0. Nevertheless, persistence with analysed anti-rheumatic medications remained similar, with no statistically significant differences, during the whole follow-up period in all groups. CONCLUSION: In early RA, the use of oral GCs is common and continues longer than recommended by the European Alliance of Associations for Rheumatology (EULAR). Persistence with treatment with MTX, bDMARDs, and JAKis in patients who continued medication was not influenced by the initial GC regimen.

Authors

Institutions

Publication Details

Journal
Scandinavian Journal of Rheumatology
Published
2026-11-13
DOI
https://doi.org/10.1080/03009742.2026.2735093
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Glucocorticoid purchases and methotrexate persistence in early rheumatoid arthritis in Finland

Maria Christina Backström, Vappu Marianna Rantalaiho, Henri Salo, Johanna A. Huhtakangas et al.
2 links
Scandinavian Journal of Rheumatology
Rheumatoid Arthritis Research and Therapies
article

Glucocorticoid purchases and methotrexate persistence in early rheumatoid arthritis in Finland

Maria Christina Backström, Vappu Marianna Rantalaiho, Henri Salo, Johanna A. Huhtakangas, Laura Kuusalo, Tuulikki Sokka, Johanna Kärki, Heikki Relas, Paula Vähäsalo, P Pöllänen
article en

Abstract

OBJECTIVE: This study aimed to explore purchases of methotrexate (MTX), biological disease-modifying anti-rheumatic drugs (bDMARDs), Janus kinase inhibitors (JAKis), and glucocorticoids (GCs) in early rheumatoid arthritis (RA) in Finland. METHOD: The study included 3046 monitored patients with early RA, who obtained reimbursement for RA medication during 2016-2020. The patients were divided into three groups according to the number of GC tablet purchases during 6 months after the reimbursement day: Group 0, no GC purchases; Group 1, purchased < 90 tablets; Group 2, purchased ≥ 90 tablets. Medication purchases were tracked in 6 month periods until the end of 2021. RESULTS: Of the monitored early RA patients, 68% purchased GCs during the initial 6 months and 43% during 6-11 months after the reimbursement date. Over 90% of the patients purchased MTX during the first year in all groups. Patients in Group 2 had the highest baseline disease activity. After the first year, the percentage of bDMARD purchasers (11% vs 6.8%, p = 0.03) and MTX users (79% vs 74%, p = 0.06) was higher in Group 2 than in Group 0. Nevertheless, persistence with analysed anti-rheumatic medications remained similar, with no statistically significant differences, during the whole follow-up period in all groups. CONCLUSION: In early RA, the use of oral GCs is common and continues longer than recommended by the European Alliance of Associations for Rheumatology (EULAR). Persistence with treatment with MTX, bDMARDs, and JAKis in patients who continued medication was not influenced by the initial GC regimen.

Scandinavian Journal of Rheumatology
University of Helsinki (FI), University of Turku (FI), Tampere University (FI), University of Eastern Finland (FI), Oulu University Hospital (FI), Helsinki University Hospital (FI), Turku University Hospital (FI), Finnish Institute for Health and Welfare (FI), Finnish Cancer Registry (FI), Kuopio University Hospital (FI), Kanta-Hämeen Keskussairaala (FI), Central Finland Health Care District (FI), The Wellbeing Services County of Ostrobothnia (FI), University of Oulu (FI)
Good health and well-being
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon